news
AI tools aid the discovery of super tight-binding antibodies
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
List view / Grid view
Covid-19
news
Host-cell factors involved in COVID-19 infections may predict improved treatments
Researchers have found a potential therapeutic target less vulnerable to potential drug resistance and emerging COVID-19 variants of concern.
article
2023 and beyond: revolutionising drug discovery
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…
news
SARS-CoV-2 antibodies can bind to two viral targets at once
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
news
Mathematical model predicts long-term effectiveness of COVID-19 vaccine
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.
news
The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes
The researchers argue hepatocytes are susceptible to SARS-CoV-2 pseudovirus infection and propose that metformin could be a therapeutic option to attenuate SARS-CoV-2 infection in patients with fatty liver.
article
Latest developments in COVID-19 research
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
article
Artificial intelligence-aided screening could boost speed of new drug discovery
Using a natural language-inspired technique, researchers at the University of Central Florida, US, developed an interpretable and generalisable drug target interaction model that achieves 97 percent accuracy in identifying drug candidates for a broad variety of target proteins. Here, Dr Ozlem Ozmen Garibay and Aida Tayebi, who worked on the…
article
Rapidly transitioning from in silico hits to leads on ‘undruggable’ pain targets
Opioid addiction is an ongoing crisis in the US. Researchers have identified a key regulator that shapes analgesic and aversive outputs of kappa opioid receptor signalling, finding lead inhibitors of this previously ‘undruggable’ target class – the Regulators of G protein Signalling (RGS proteins) – to help re-establish non-addictive kappa…
news
Experimental mRNA vaccine protects against all 20-subtype influenza viruses
US researchers have tested mRNA-based vaccine against influenza viruses, with promising results in animal models, that pave the way for clinical trials.
news
New drug shows promise for fighting both COVID-19 and cancer
US researchers showed that the protein: GRP78, implicated in COVID-19 and cancers, is effected by the new drug HA15.
news
Cancer immunotherapy adapted to treat COVID-19 variants
US researchers have utilised a cancer immunotherapy technique, CAR-T cell method to effectively eliminate SARS-CoV-2 virus pre- and post-infection in vitro.
news
SK bioscience collaborates with IVI to support global R&D
SK bioscience and IVI convened in consultative meeting to discuss cooperation for next pandemic and announced KRW3 billion donation to IVI to support advancement of global vaccine R&D
news
SARS-CoV-2 blocked by antiviral substances discovered in South Korean plants
South Korean researchers identified two saponins there were highly effective in blocking the ability of SARS-CoV-2 variants to enter cells.
news
Novel nasal vaccine strategy could improve COVID-19 protection
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
